PharmaCyte Biotech, Inc. (PMCB)
After hours:
| Previous Close | 2.1700 |
| Open | 2.1200 |
| Bid | 1.5800 x 200 |
| Ask | 2.7100 x 200 |
| Day's Range | 2.1200 - 2.2500 |
| 52 Week Range | 1.9200 - 3.2300 |
| Volume | |
| Avg. Volume | 26,146 |
| Market Cap | 17.921M |
| Beta (5Y Monthly) | -0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4800 |
| Earnings Date | Mar 11, 2024 - Mar 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company’s first investment in externally dev
GlobeNewswireFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unme
- Business Wire
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
LAS VEGAS, October 31, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In
